Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 31,033 Shares

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 31,033 shares of the stock in a transaction dated Friday, March 21st. The stock was bought at an average price of $12.78 per share, with a total value of $396,601.74. Following the acquisition, the director now owns 17,135,113 shares in the company, valued at approximately $218,986,744.14. This represents a 0.18 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, March 26th, Ecor1 Capital, Llc bought 43,848 shares of Zymeworks stock. The stock was purchased at an average cost of $12.24 per share, with a total value of $536,699.52.
• On Monday, March 24th, Ecor1 Capital, Llc acquired 22,689 shares of Zymeworks stock. The stock was purchased at an average price of $13.08 per share, with a total value of $296,772.12.
• On Wednesday, March 19th, Ecor1 Capital, Llc bought 58,306 shares of Zymeworks stock. The shares were acquired at an average price of $12.64 per share, for a total transaction of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The shares were acquired at an average price of $12.23 per share, with a total value of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was acquired at an average price of $12.48 per share, for a total transaction of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc purchased 320,690 shares of Zymeworks stock. The shares were bought at an average cost of $11.49 per share, for a total transaction of $3,684,728.10.
• On Friday, January 17th, Ecor1 Capital, Llc acquired 19,748 shares of Zymeworks stock. The shares were bought at an average cost of $13.87 per share, with a total value of $273,904.76.
• On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The stock was bought at an average price of $14.01 per share, for a total transaction of $546,796.29.
• On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The shares were bought at an average cost of $13.39 per share, with a total value of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were purchased at an average price of $13.13 per share, with a total value of $2,679,806.74.

Zymeworks Trading Down 1.1 %

ZYME traded down $0.14 during midday trading on Friday, hitting $12.37. The company's stock had a trading volume of 320,353 shares, compared to its average volume of 598,132. Zymeworks Inc. has a 52-week low of $7.97 and a 52-week high of $17.70. The firm has a 50-day moving average price of $13.60 and a two-hundred day moving average price of $13.72. The firm has a market cap of $860.67 million, a P/E ratio of -8.25 and a beta of 1.13.

Remove Ads

Institutional Trading of Zymeworks

Several institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its position in Zymeworks by 0.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 132,798 shares of the company's stock valued at $1,667,000 after acquiring an additional 650 shares during the period. Nuveen Asset Management LLC lifted its stake in shares of Zymeworks by 0.4% in the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company's stock valued at $3,031,000 after purchasing an additional 886 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Zymeworks by 6.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company's stock worth $214,000 after purchasing an additional 940 shares during the period. Sterling Capital Management LLC increased its position in Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock worth $25,000 after purchasing an additional 1,524 shares in the last quarter. Finally, FMR LLC lifted its position in Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after buying an additional 1,525 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZYME has been the subject of several analyst reports. Citigroup increased their price target on shares of Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, March 7th. HC Wainwright boosted their price target on Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Monday, March 10th. Wells Fargo & Company boosted their target price on Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research report on Thursday, December 19th. Lifesci Capital initiated coverage on Zymeworks in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price target for the company. Finally, JPMorgan Chase & Co. raised shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective on the stock in a research note on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $21.00.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.